Trial results for a multiomics blood-based test for the prevention of Colorectal Cancer were posted on ClinicalTrials.gov on 2025-12-05, reporting a sensitivity of 79.2% for colorectal cancer.
Background
Colorectal cancer (CRC) remains a significant public health challenge, with early detection being crucial for improving patient outcomes. Current screening methods, such as colonoscopy, are effective but can be invasive and may face adherence barriers. Non-invasive screening options, like blood-based tests, hold promise for increasing screening rates and detecting cancer at earlier, more treatable stages. The PREEMPT CRC study aimed to validate such a blood-based test for the early detection of colorectal cancer in average-risk individuals.
Trial design
The PREEMPT CRC study was a completed multi-center observational study that enrolled 48,995 participants. The study focused on the prevention of Colorectal Cancer by validating a blood-based test for early detection. Participants were average-risk individuals undergoing routine screening colonoscopy, with the study collecting blood samples for analysis. The conditions investigated included Colon Cancer, Rectal Cancer, Colon Neoplasm, Colon Diseases, and Colon Lesion.
Key results
The trial reported several key measurements for the performance of the blood-based test in evaluable subjects:
- Sensitivity for Colorectal Cancer: 79.2 Percent.
- Specificity for Advanced Colorectal Neoplasia: 91.5 Percent.
- Negative Predictive Value for Advanced Colorectal Neoplasia: 90.8 Percent.
- Positive Predictive Value for Advanced Colorectal Neoplasia: 15.5 Percent.
- Sensitivity for Advanced Precancerous Lesion: 12.5 Percent.
- Census-adjusted Sensitivity for Colorectal Cancer: 81.1 Percent.
- Census-adjusted Specificity for Advanced Colorectal Neoplasia: 90.4 Percent.
- Census-adjusted Negative Predictive Value for Advanced Colorectal Neoplasia: 90.5 Percent.
- Census-adjusted Positive Predictive Value for Advanced Colorectal Neoplasia: 15.5 Percent.
- Census-adjusted Sensitivity for Advanced Precancerous Lesion: 13.7 Percent.
What this means
The results from the PREEMPT CRC study indicate that the multiomics blood-based test demonstrated promising performance for the early detection of colorectal cancer, with a sensitivity of 79.2% and a specificity of 91.5% for advanced colorectal neoplasia. These figures suggest its potential as a non-invasive screening tool, which could help overcome barriers associated with traditional screening methods. However, the sensitivity for advanced precancerous lesions was considerably lower at 12.5%, indicating limitations in detecting very early-stage or pre-malignant changes. While these results support the utility of such a test for detecting established colorectal cancer, further research may be needed to enhance its ability to identify precancerous lesions.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for the study titled 'Prevention of Colorectal Cancer Through Multiomics Blood Testing' were posted on 2025-12-05 on clinicaltrials.gov.